KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Debt: 2009-2024

Historic Non-Current Debt for Ionis Pharmaceuticals (IONS) over the last 13 years, with Dec 2024 value amounting to $51.9 million.

  • Ionis Pharmaceuticals' Non-Current Debt rose 24.11% to $51.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.9 million, marking a year-over-year increase of 24.11%. This contributed to the annual value of $51.9 million for FY2024, which is 24.11% up from last year.
  • As of Q4 2024, Ionis Pharmaceuticals' Non-Current Debt stood at $51.9 million, which was up 24.11% from $41.8 million recorded in Q4 2023.
  • Ionis Pharmaceuticals' Non-Current Debt's 5-year high stood at $60.0 million during Q2 2021, with a 5-year trough of $8.8 million in Q1 2023.
  • For the 3-year period, Ionis Pharmaceuticals' Non-Current Debt averaged around $42.3 million, with its median value being $51.9 million (2024).
  • Data for Ionis Pharmaceuticals' Non-Current Debt shows a peak YoY increase of 161.92% (in 2023) and a maximum YoY decrease of 85.18% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Non-Current Debt stood at $60.0 million in 2020, then declined by 0.45% to $59.7 million in 2021, then slumped by 73.25% to $16.0 million in 2022, then surged by 161.92% to $41.8 million in 2023, then rose by 24.11% to $51.9 million in 2024.
  • Its last three reported values are $51.9 million in Q4 2024, $41.8 million for Q4 2023, and $8.8 million during Q1 2023.